Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
09 juin 2023 03h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics to Participate in Upcoming June Investor Conference
01 juin 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
22 mai 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
19 mai 2023 07h00 HE
|
Kymera Therapeutics, Inc.
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of...
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
18 mai 2023 07h00 HE
|
Kymera Therapeutics, Inc.
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis...
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
04 mai 2023 07h00 HE
|
Kymera Therapeutics, Inc.
Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023;Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for...
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
11 avr. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
01 mars 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
23 févr. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing,with data evaluating clinical...
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
01 févr. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...